Skip to main content
. 2021 Feb 16;10(2):406. doi: 10.3390/cells10020406

Table 2.

Clinical features with respect to checkpoint inhibitor therapy for Overall Response Rate.

ECOG (**)
0 1 2 Total
CR/PR 10 (58.8%) 7 (41.2%) 0 (0%) 17 (100%)
PD 8 (18.6%) 21 (48.8%) 14 (32.6%) 43 (100%)
Total 18 (30.0%) 28 (46.7%) 14 (23.3%) 60 (100%)
Number of Metastatic Sites (*)
CR/PR < 3 ≥3 Total
9 (52.9%) 8 (47.1%) 17 (100%)
PD 13 (30.2%) 30 (69.8%) 43 (100%)
Total 22 (36.7%) 38 (63.3%) 60 (100%)
Age (*)
CR/PR 72 (64–76)
PD 64 (54–72)

* p-value < 0.10; ** p-value < 0.05.